Melina Marmarelis, MD, on Combining Pembrolizumab and Itacitinib in PD-L1–Positive NSCLC

Posted: Wednesday, November 13, 2024

Melina Marmarelis, MD, of the Hospital of the University of Pennsylvania, provides an update on the long-term outcomes of combining the PD-1 inhibitor pembrolizumab and the JAK inhibitor itacitinib in the treatment of PD-L1–positive non–small cell lung cancer (NSCLC). She also briefly explains how interferon signaling modulation through JAK inhibition may help to prevent resistance to immunotherapy in these patients.

---